Teragen Bio Selected as Contractor for 'AI Software Solution Development for Pediatric Rare Diseases' Project

[Asia Economy Reporter Lee Gwan-joo] Theragen Bio announced on the 22nd that it has been selected as the project operator for the 'Development of Pediatric Rare Disease Multi-Analysis AI Integrated Software (SW) Solution' in collaboration with Seoul National University Hospital and Kakao Healthcare Consortium.

The project, led by the Institute for Information & Communications Technology Planning and Evaluation, will receive a total research fund of 9.7 billion KRW by 2024. The goal is to develop cloud-based software solutions including diagnostic AI models and prognosis management AI models for nine groups of pediatric rare diseases. A total of five hospitals, including Seoul National University Hospital, Seoul St. Mary's Hospital, Samsung Seoul Hospital, Pusan National University Hospital, and Kyungpook National University Hospital, along with four software development companies including Theragen Bio and Kakao Healthcare, are participating.

In this project, Theragen Bio plans to propose treatment solutions for rare disease patients and produce sequencing data for validating diagnostic software. To this end, it will analyze approximately 33 million biomedical literature documents using AI technology and conduct text mining on pediatric rare diseases to develop algorithms that propose diagnostic and treatment solutions. Additionally, a total of 13 hospitals, including eight nationwide clinical validation network hospitals such as Chungbuk National University Hospital, Inha University Hospital, Chungnam National University Hospital, Boramae Medical Center, Jeju National University Hospital, Ajou University Hospital, and St. Vincent's Hospital, will build whole genome data for 900 patients to validate the pediatric rare disease AI software.

Hwang Tae-soon, CEO of Theragen Bio, said, “We are pleased to contribute to the accurate and rapid diagnosis of pediatric rare disease patients through Theragen Bio’s extensive genome analysis experience and to strengthen the company’s social responsibility,” adding, “We will become a company that contributes to technological development that benefits the world.”

This content was produced with the assistance of AI translation services.